Advantage Partners has appointed Shinichiro Kita as head of its Japan buyout team as part of succession planning within the Japanese firm. The change also ties into efforts to create more synergies between the buyout operation and an expanded public markets investment strategy.
Kita (pictured), a senior partner who joined Advantage in 2003, has been running Japan buyouts on a day-to-day basis alongside Hideo Nagatsuyu for several years. His promotion formalizes this arrangement,...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.